1.A Case of Leflunomide Induced Vasculitis.
Kyu LEE ; Dong Gyu KIM ; Ji Hyun OH ; Dong Il LEE ; Choong Won LEE
The Journal of the Korean Rheumatism Association 2004;11(4):459-460
No abstract available.
Vasculitis*
2.Pulmonary vasculitis.
Tuberculosis and Respiratory Diseases 2000;48(6):825-836
No abstract available.
Vasculitis*
3.Vasculitis: Etiology and Clinical Features.
Journal of the Korean Society for Vascular Surgery 2005;21(2):190-193
No abstract available.
Vasculitis*
4.Clinical Manifestations and Significance of Mononeuritis Multiplex in Systemic Necrotizing Vasculitis.
Jinseok KIM ; Hoon Suk CHA ; Gi Hyun SEO ; Hong Joon AHN ; Chang Keun LEE ; Jae Hyun KOH ; Hyeon Sook KIM ; Dong Chull CHOI ; Eun Mi KOH
The Journal of the Korean Rheumatism Association 1999;6(1):23-30
No abstract available.
Mononeuropathies*
;
Systemic Vasculitis
;
Vasculitis*
5.Nodular Vasculitis Associated with Cefazolin.
Jae Hwa KIM ; Joong Sun LEE ; Dae Won KOO ; Kyung Eun JUNG
Korean Journal of Dermatology 2017;55(8):553-555
No abstract available.
Cefazolin*
;
Vasculitis*
6.Lupus Mesenteric Vasculitis Limited in Stomach.
Jae Ho LEE ; Seung Ki KWOK ; Sung Hwan PARK
Journal of Rheumatic Diseases 2012;19(4):234-235
No abstract available.
Stomach
;
Vasculitis
9.Bullous Necrotizing Vasculitis of the Skin.
Pyung Won PARK ; Chang Woo LEE ; Jae Hong KIM
Annals of Dermatology 1993;5(2):113-116
Three cases of necrotizing vasculitis clinically showing bullous skin lesions and histopathologically confirmed as leukocytoclastic vasculitis are reported. Compared with those of skin -limited non-bullous forms of cutaneous vasculitis, these cases showed relatively frequent abnormalities in urinalysis and required more aggresive corticosteriod therapy. Clinicians should be aware of the possible systemic involvements when the skin lesions are bullous in cutaneous necrotizing vasculitis.
Skin*
;
Urinalysis
;
Vasculitis*
10.Treatment with Low-Dose Danazol in Livedo Vasculitis.
Korean Journal of Dermatology 1999;37(2):163-167
BACKGROUND: Several modalities have been used for the treatment of livedo vasculitis. However, in some cases conspicious morbidity is caused by recurrent painful ulceration resistant to therapy. OBJECTIVE: This study was conducted to determine the effectiveness and adverse effects of the danazol in treatment of livedo vasculitis. METHODS: Nine patients with ulcerative lesions due to livedo vasculitis were included for danazol therapy. Danazol 200mg was administered daily for 4 to 8 weeks. RESULTS: Eight of the patients showed remarkable improvement and were satisfied with this therapy. Significant adverse effects were not observed. CONCLUSION: We suggest that a low dose of danazol may be considered as the first line of treatment and is worthwhile to try in cases recalcitrant to the other treatment.
Danazol*
;
Humans
;
Ulcer
;
Vasculitis*
Result Analysis
Print
Save
E-mail